Poorly Soluble Drugs
Currently, about 40% of drug development candidates and approximately 70% of new drug leads have low aqueous solubility. Poor solubility creates drug delivery challenges such as erratic absorption and low oral bioavailability. CPES has a range of enabling technologies that can be used to design a formulation that will enhance the solubility of your active.
We can investigate a number of approaches:
- Amorphous Forms
- Co-crystals and novel polymorphs
- Micronisation and Nanoprocessing